Consortium of Multiple Sclerosis Centers Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2012
NCT01516554
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Consortium of Multiple Sclerosis Centers

Active Ingredients

Drugs in Phase 2 Trials (2)

bisacodyl (Halflytely) (1 trial)

testosterone (delatestryl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Constipation (Phase 2)

Fatigue (Phase 2)

Fecal Incontinence (Phase 2)

Multiple Sclerosis (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2